Digest Réseau Comment ça marche
Réseau
/
Sociétés
A2
Non vérifié

A2 Biotherapeutics, Inc.

Ce que nous écrivons

BiotechnologieIndustrie pharmaceutiqueMédecine - DiversOncologieSanté

10 communiqués de presse

Voir tous les communiqués de presse
22/04/2026
Événements
Industrie
Biotechnologie
Santé
Industrie pharmaceutique
Médecine - Divers
Oncologie
A2 Biotherapeutics to Highlight Progress of CAR T-Cell Clinical Programs in Three Poster Presentations During the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
Source
A2 Biotherapeutics, Inc.
Émetteur
Business Wire
1.00
0
01/04/2026
Industrie
Biotechnologie
Hygiène alimentaire
Santé
Industrie pharmaceutique
Oncologie
A2 Biotherapeutics Receives U.S. FDA Fast Track Designation for A2B543, a Logic-Gated CAR T-Cell Therapy Enhanced with a Membrane-Tethered IL-12 Booster
Source
A2 Biotherapeutics, Inc.
Émetteur
Business Wire
1.00
0
26/02/2026
Industrie
Science
Biotechnologie
Industrie pharmaceutique
Oncologie
Santé
Médecine - Divers
A2 Biotherapeutics Doses First Patient in EVEREST-2 Study with A2B543, a Logic-Gated CAR T Cell Therapy Enhanced with a Membrane-Tethered IL-12 Booster
Source
A2 Biotherapeutics, Inc.
Émetteur
Business Wire
1.00
0
08/01/2026
Industrie
Science
Hygiène alimentaire
Biotechnologie
Médecine - Divers
Santé Publique
Industrie pharmaceutique
Santé
Oncologie
A2 Biotherapeutics Announces FDA Clearance of IND for A2B543 for Treatment of Adults with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors that Express Mesothelin and Have Lost HLA-A*02 Expression
Source
A2 Biotherapeutics, Inc.
Émetteur
Business Wire
1.00
0
03/10/2025
Science
Biotechnologie
Industrie pharmaceutique
Oncologie
Santé Publique
Santé
Médecine - Divers
Événements
Industrie
A2 Bio to Present Early Safety and Efficacy Data from EVEREST-2 Study during 2025 Annual Meeting of the Society for Immunotherapy of Cancer
Source
A2 Biotherapeutics, Inc.
Émetteur
Business Wire
1.00
0
08/09/2025
Biotechnologie
Santé
Industrie pharmaceutique
Médecine - Divers
Oncologie
Événements
Industrie
A2 Biotherapeutics Presents Data from Ongoing Phase 1/2 EVEREST-2 Study During the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer
Source
A2 Biotherapeutics, Inc.
Émetteur
Business Wire
1.00
0
26/06/2025
Oncologie
Santé
Biologie
Biotechnologie
Médecine - Divers
Industrie pharmaceutique
Industrie
A2 Bio Announces First Patient Dosed in DENALI-1 Phase 1/2 Clinical Study of A2B395, a Novel Allogeneic Precision CAR T Cell Therapy for Patients with Solid Tumors that Express EGFR
Source
A2 Biotherapeutics, Inc.
Émetteur
Business Wire
1.00
0
09/01/2025
Industrie
Oncologie
Santé
Biotechnologie
Médecine - Divers
Industrie pharmaceutique
A2 Biotherapeutics Closes $80 Million Series C Financing to Advance Clinical Development of Its Precision Cell Therapies Using Its Proprietary Tmod™ Technology Platform
Source
A2 Biotherapeutics, Inc.
Émetteur
Business Wire
1.00
0
09/11/2024
Événements
Biotechnologie
Santé
Industrie pharmaceutique
Médecine - Divers
Oncologie
A2 Bio Highlights Progress of Tmod™ CAR T-Cell Clinical Programs During 2024 Annual Meeting of the Society for Immunotherapy of Cancer
Source
A2 Biotherapeutics, Inc.
Émetteur
Business Wire
1.00
0
04/10/2024
Événements
Industrie
Oncologie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
A2 Bio to Present Safety and Biomarker Data from EVEREST-1 Trial during 2024 Annual Meeting of the Society for Immunotherapy of Cancer
Source
A2 Biotherapeutics, Inc.
Émetteur
Business Wire
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0